A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab

Inclusion Criteria:

• Locally advanced or metastatic and/or unresectable HCC with diagnosis confirmed byhistology/ cytology or clinically by American Association for the Study of LiverDiseases (AASLD) criteria in cirrhotic patients.

• Disease progression following prior atezolizumab plus bevacizumab combinationtreatment for HCC, for at least 4 consecutive treatment cycles, and 2 subsequenttumor assessments. It is required that at least 1 tumor assessment shows eitherstable disease (SD), partial response (PR), or complete response (CR).

• At least one measurable (per RECIST v1.1) target lesion that has not been previouslytreated with local therapy or, if the target lesion is within the field of previouslocal therapy, has subsequently progressed in accordance with RECIST v1.1.

• Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1 within 7days prior to randomization

• Child-Pugh class A within 7 days prior to randomization

• Adequate hematologic and end-organ function

Exclusion Criteria:

• Symptomatic, untreated, or actively progressing central nervous system (CNS)metastases.

• History of leptomeningeal disease

• History of hepatic encephalopathy, preceding 6 months, unresponsive to therapywithin 3 days

• Known fibrolamellar HCC, sarcomatoid HCC, or mixed cholangiocarcinoma and HCC

• History of malignancy other than HCC within 5 years prior to screening, with theexception of malignancies with a negligible risk of metastasis or death